The pathway analyses particularly demonstrated CD164’s dual role in promoting oncogenic signaling (PI3K-Akt, TGF-β) while suppressing tumor-suppressive metabolic pathways (AMPK, butyrate metabolism), providing mechanistic insight into its pro-tumorigenic effects. Here, AKT1 is linked to neoplasm.